Brief: AC Immune To Present Data From Phase II Crenezumab Alzheimer’s Prevention Initiative Study

AC Immune AG

02/08/2022 17:09

Aug 2 (Reuters) - AC Immune SA  ACIU.O :
    * DETAILED DATA FROM THE PHASE II CRENEZUMAB ALZHEIMER’S
PREVENTION INITIATIVE STUDY IN AUTOSOMAL DOMINANT ALZHEIMER’S
DISEASE PRESENTED AT AAIC
    * AC IMMUNE SA - CRENEZUMAB WAS SAFE AND WELL TOLERATED WITH
NO
CASES OF ARIA-E OBSERVED DURING UP TO EIGHT-YEAR STUDY

Source text for Eikon:  ID:nGNX1yh8Ds 
Further company coverage:  ACIU.O 

 ((Reuters.Briefs@thomsonreuters.com;))